ES2627099T3 - Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR - Google Patents
Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR Download PDFInfo
- Publication number
- ES2627099T3 ES2627099T3 ES13827913T ES13827913T ES2627099T3 ES 2627099 T3 ES2627099 T3 ES 2627099T3 ES 13827913 T ES13827913 T ES 13827913T ES 13827913 T ES13827913 T ES 13827913T ES 2627099 T3 ES2627099 T3 ES 2627099T3
- Authority
- ES
- Spain
- Prior art keywords
- diseases related
- diseases
- alkyl
- treatment
- mtor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010099 disease Diseases 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 9
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 title abstract 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 title abstract 3
- 230000037361 pathway Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 229920002527 Glycogen Polymers 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 229940096919 glycogen Drugs 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000005934 immune activation Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000002364 leukopenia Diseases 0.000 abstract 1
- 231100001022 leukopenia Toxicity 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/62—Carboxylic acid nitriles containing cyano groups and oxygen atoms being part of oxyimino groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
Abstract
Un compuesto de la Fórmula (I): o una sal aceptable farmacéuticamente, o solvato de este, para usar en el tratamiento de una o más enfermedades relacionadas con la vía de mTOR, en donde la una, o más enfermedades relacionadas con la vía de mTOR se seleccionan de enfermedades neurodegenerativas, enfermedades relacionadas con la edad, enfermedades relacionadas con el rechazo de trasplante, enfermedades inflamatorias crónicas, enfermedades relacionadas con el almacenamiento de glucógeno, lupus sistémico, enfermedades relacionadas con la inflamación y la activación inmune, anemia, leucopenia, trombocitopenia, enfermedades relacionadas con el recubrimiento de endoprótesis, insuficiencia renal, obesidad, diabetes/resistencia a la insulina, enfermedades relacionadas con el hígado graso no alcohólico, riñón poliquístico y fibrosis y en donde, R1 es -CN; R2 y R3 y R5 cada uno se selecciona independientemente de H, alquilo, halógeno, -CF3 o -CN; R4 y R6 cada uno se selecciona independientemente de H, alquilo, halógeno, alcoxi, -CF3, -OCF3, -SO2CF3, - SOCF3 o -SCF3; X es un heteroátomo, N(alquil) o NH; y n es de 1 a 20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012903365A AU2012903365A0 (en) | 2012-08-06 | Compounds for the treatment of mTOR pathway related diseases | |
| PCT/AU2013/000859 WO2014022879A1 (en) | 2012-08-06 | 2013-08-05 | Compounds for the treatment of mtor pathway related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2627099T3 true ES2627099T3 (es) | 2017-07-26 |
Family
ID=50067298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13827913T Active ES2627099T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR |
| ES17162895T Active ES2757598T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de las enfermedades relacionadas con la vía mTOR |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17162895T Active ES2757598T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de las enfermedades relacionadas con la vía mTOR |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9790176B2 (es) |
| EP (2) | EP2880014B1 (es) |
| JP (2) | JP6441219B2 (es) |
| KR (1) | KR102124392B1 (es) |
| CN (2) | CN104837812B (es) |
| AU (2) | AU2013302209B2 (es) |
| CA (1) | CA2881325C (es) |
| ES (2) | ES2627099T3 (es) |
| NZ (2) | NZ631523A (es) |
| PL (1) | PL2880014T3 (es) |
| WO (1) | WO2014022879A1 (es) |
| ZA (1) | ZA201501390B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2880014T3 (pl) * | 2012-08-06 | 2017-10-31 | Pitney Pharmaceuticals Pty Ltd | Związki do leczenia chorób związanych ze szlakiem mTOR |
| KR102271848B1 (ko) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | 암 치료용 약학적 배합물 |
| WO2015171723A1 (en) * | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
| US10391076B2 (en) * | 2015-02-24 | 2019-08-27 | Pitney Pharmaceuticals Pty Ltd. | Anti-cancer agent comprising aminoacetonitrile compound as active ingredient |
| HUE061437T2 (hu) | 2015-10-23 | 2023-06-28 | Navitor Pharm Inc | A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai |
| US10912750B2 (en) | 2017-04-26 | 2021-02-09 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
| CA3156436A1 (en) * | 2019-11-01 | 2021-05-06 | Steven LEVENTER | Methods of treatment using an mtorc1 modulator |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| CN113577086B (zh) * | 2020-04-30 | 2023-05-02 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
| EP4149454A4 (en) * | 2020-05-11 | 2024-10-16 | Pitney Pharmaceuticals Pty Limited | Use of aminoacetonitrile compounds for the treatment of infection and disease |
| CN115304600B (zh) * | 2022-09-29 | 2023-01-13 | 北京鑫开元医药科技有限公司 | mTOR抑制剂、制备方法及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6239077B1 (en) * | 1998-05-01 | 2001-05-29 | Nihon Nohyaku Co., Ltd. | Aminoacetonitrile derivative agricultural and horticultural insecticide containing the same and use thereof |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| TWI292712B (en) * | 2000-12-20 | 2008-01-21 | Novartis Ag | Aminoacetonitrile compounds for use in the control of endoparasites |
| AU2005303993B2 (en) * | 2004-11-09 | 2009-10-29 | Elanco Tiergesundheit Ag | Process for the preparation of enantiomers of amidoacetonitrile compounds from their racemates |
| US20090286838A1 (en) * | 2004-12-06 | 2009-11-19 | Newsouth Innovations Pty Limited | Treatment for cancer |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| WO2013138863A1 (en) * | 2012-03-23 | 2013-09-26 | Newsouth Innovations Pty Limited | Kinase inhibitors for the treatment of cancer |
| PL2880014T3 (pl) | 2012-08-06 | 2017-10-31 | Pitney Pharmaceuticals Pty Ltd | Związki do leczenia chorób związanych ze szlakiem mTOR |
| KR102271848B1 (ko) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | 암 치료용 약학적 배합물 |
-
2013
- 2013-08-05 PL PL13827913T patent/PL2880014T3/pl unknown
- 2013-08-05 WO PCT/AU2013/000859 patent/WO2014022879A1/en not_active Ceased
- 2013-08-05 NZ NZ631523A patent/NZ631523A/en unknown
- 2013-08-05 US US14/420,081 patent/US9790176B2/en active Active
- 2013-08-05 CN CN201380051602.3A patent/CN104837812B/zh active Active
- 2013-08-05 KR KR1020157003924A patent/KR102124392B1/ko active Active
- 2013-08-05 ES ES13827913T patent/ES2627099T3/es active Active
- 2013-08-05 ES ES17162895T patent/ES2757598T3/es active Active
- 2013-08-05 JP JP2015525692A patent/JP6441219B2/ja active Active
- 2013-08-05 CN CN201510883323.4A patent/CN105496999A/zh active Pending
- 2013-08-05 EP EP13827913.8A patent/EP2880014B1/en active Active
- 2013-08-05 AU AU2013302209A patent/AU2013302209B2/en active Active
- 2013-08-05 NZ NZ729555A patent/NZ729555A/en not_active IP Right Cessation
- 2013-08-05 CA CA2881325A patent/CA2881325C/en active Active
- 2013-08-05 EP EP17162895.1A patent/EP3202397B1/en active Active
-
2015
- 2015-03-02 ZA ZA2015/01390A patent/ZA201501390B/en unknown
-
2016
- 2016-09-28 AU AU2016234924A patent/AU2016234924B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/613,635 patent/US10053422B2/en active Active
-
2018
- 2018-01-12 JP JP2018003249A patent/JP6509386B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015524446A (ja) | 2015-08-24 |
| AU2016234924B2 (en) | 2017-04-13 |
| JP6441219B2 (ja) | 2018-12-19 |
| ES2757598T3 (es) | 2020-04-29 |
| CN104837812A (zh) | 2015-08-12 |
| CN105496999A (zh) | 2016-04-20 |
| CA2881325A1 (en) | 2014-02-13 |
| US9790176B2 (en) | 2017-10-17 |
| AU2013302209A1 (en) | 2015-02-19 |
| NZ729555A (en) | 2017-08-25 |
| US20150166477A1 (en) | 2015-06-18 |
| CA2881325C (en) | 2020-09-29 |
| US20170369435A1 (en) | 2017-12-28 |
| EP2880014B1 (en) | 2017-05-17 |
| KR20150081422A (ko) | 2015-07-14 |
| EP3202397B1 (en) | 2019-09-25 |
| NZ631523A (en) | 2017-03-31 |
| JP2018062526A (ja) | 2018-04-19 |
| PL2880014T3 (pl) | 2017-10-31 |
| HK1205502A1 (en) | 2015-12-18 |
| WO2014022879A1 (en) | 2014-02-13 |
| AU2013302209B2 (en) | 2016-09-29 |
| EP3202397A1 (en) | 2017-08-09 |
| CN104837812B (zh) | 2017-09-26 |
| EP2880014A1 (en) | 2015-06-10 |
| ZA201501390B (en) | 2017-09-27 |
| US10053422B2 (en) | 2018-08-21 |
| AU2016234924A1 (en) | 2016-10-20 |
| KR102124392B1 (ko) | 2020-06-19 |
| EP2880014A4 (en) | 2015-12-30 |
| JP6509386B2 (ja) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2627099T3 (es) | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR087870A1 (es) | Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina | |
| UY33842A (es) | ?pesticidas mesoiónicos?. | |
| AR081203A1 (es) | Pirrolopirazinas como inhibidores de quinasas | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| EP4295841A3 (en) | Sulfur (vi) fluoride compounds and their use in click-reaction | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| MX2022008434A (es) | Herbicidas de piridazinona. | |
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| JP2010504286A5 (es) | ||
| JP2013542218A5 (es) | ||
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| EA201590281A1 (ru) | Новые гетероарильные и гетероциклические соединения, их композиции и способы | |
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| MX2015012629A (es) | Compuestos de imidazo piridina. | |
| MX2009008509A (es) | Compuesto de anillo puenteado-aza. | |
| WO2013076315A3 (en) | Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| PE20150182A1 (es) | Compuestos de fenoxietil piperidina | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| IN2014DN01993A (es) | ||
| MX2015014406A (es) | Carboxamidas fungicidas. |